Ortho Clinical Diagnostics
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, Bruker, 10x Genomics, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.
QuidelOrtho Preliminary Q4 Earnings Beat Estimates
The firm expects its Q4 non-COVID core revenues to increase approximately 18 percent and full-year core revenues to increase approximately 11 percent.
The firm also said it will shift its near-term regulatory and commercial strategy for its Savanna molecular diagnostic instrument.
QuidelOrtho Reports Preliminary Q3 Revenues
The firm forecast preliminary revenues in the range of $782 million to $785 million for the first full quarter since the merger of Quidel and Ortho Clinical Diagnostics.
QuidelOrtho Board Authorizes $300M Share Repurchase
The firm said it will repurchase up to $300 million in shares of common stock while also prioritizing R&D and manufacturing expansion.